Health & Biotech ASX Health Stocks: Oncosil advances pancreatic cancer device to Greece, its third potential market in Europe December 8, 2023 Oncosil says first two patient treatments using OncoSil device happened in Greece. Nova Eye gets temporary reprieve on US Medicare… Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX December 8, 2023 With its erectile dysfunction nasal spray treatment in advanced development, LTR Pharma is creating buzz ahead of its ASX listing… ASX Health Stocks: Imagion and Microba’s positive Phase 1 results; and LGP’s first mover advantage in France December 7, 2023 Imagion announced positive results from Phase 1 breast cancer study. Little Green Pharma to capitalise on first mover advantage in… The ASX stocks hoping to profit from the endless search for an ‘elixir of youth’ December 7, 2023 The quest for the elixir of youth has become big business and led to a thriving industry with these ASX… Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot December 7, 2023 Expert says global cannabis boom is a matter of if, not when Catalyst will be US DEA's pending decision to… ASX Health Stocks: Imugene wins ‘intention to grant’ cancer vaccine patent, Phase 2 trial in 2024 December 6, 2023 Imugene issued “Intention to Grant “ notice by European Patent Office. The patent will be given to its PD1-Vaxx cancer… PharmAust bolsters leadership as CEO attends global ALS/MND Symposium December 6, 2023 PharmAust is beefing up its management team with two key appointments in preparation for upcoming regulatory and clinical milestones for… ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome December 5, 2023 Neuren Pharma completes Phase 2 patient enrolment, while Cyclopharm signed a deal with globally respected Duke University Hospital. Neurotech to extend Phase 2/3 autism spectrum disorder trial to adults December 4, 2023 Special Report: Neurotech’s Phase 2/3 clinical trial in autism spectrum disorder (ASD) has hit another milestone after receiving approval to… ASX Health Stocks: Compumedics granted FDA clearance; Botanix receives FDA feedback December 4, 2023 Compumedics scores FDA approval for sleep device, and FDA said Botanix's materials for its NDA submission are acceptable. Next» « Previous